Adam Feuerstein On The AASLD Meeting-Abbott vs. Gilead
Biotech
Biotech Stock Mailbag: Sarepta, Acadia, Vical and a Hep C Preview
Excerpt – click here to read complete article
Gary B. emails, “What are your predictions for hepatitis C stocks at the meeting this weekend?”
I predict chaos and confusion. I long ago stopped expecting closure or certainty from these AASLD meetings. Hepatitis C drug development is too volatile.
Here’s what to look for this weekend:
The AASLD media embargo lifts on Saturday at 9 a.m. Eastern time.
Abbott(ABT) and Gilead Sciences(GILD) have told me that press releases with up-to-date data on their respective all-oral regimens will be issued at that time.
Abbott vs. Gilead is the main event at AASLD this year.
Abbott has set the efficacy bar high already with SVR12 “cure” rates of 96% to 99% in treatment-naive genotype 1 patients treated in its “AVIATOR” phase II study.
The Abbott drugs studied in AVIATOR were ABT-450, a protease inhibitor that requires blood-boosting with ritonavir; ABT-267, a NS5A inhibitor; and ABT-333, a “non-nuc” polymerase inhibitor. Ribavirin, a current backbone in hepatitis C treatment, was also included in some but not all of the combination regimens.
On Saturday, Abbott will announce updated results from the AVIATOR study.
Gilead will counter with SVR4 cure-rate data from the ELECTRON study involving a combination regimen of the nucleoside inhibitor GS-7977 and the NS5A inhibitor GS-5885, plus or minus ribavirin. ELECTRON also enrolls treatment-naive, genotype 1 hepatitis C patients.
Bristol-Myers Squibb(BMY) may shine on the undercard. Watch for SVR12 cure-rate data from the phase II combination of Bristol’s NS5A inhibitor daclatasvir in combination with Gilead’s GS-7997. While this combination isn’t being moved into phase III, results will be viewed as a proxy for Gilead’s ’7977/’5885 combination.
On its own, Bristol will also be presenting data on a combination therapy involving daclatasvir, asunaprevir (a protease inhibitor) and the non-nuc BMS-791325.
I’m attending the AASLD meeting, which starts tomorrow and runs through Tuesday, so I’ll have lots more to say about hepatitis C over the weekend and next week.
Continue Reading @ The Street
Read previous and future articles by Adam Feuerstein here….
2012-11-09 19:51:45
Source: http://hepatitiscnewdrugs.blogspot.com/2012/11/adam-feuerstein-on-aasld-meeting-abbott.html
Source:
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).